NCT06595108 Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
| NCT ID | NCT06595108 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Advanced Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 33 participants |
| Start Date | 2024-05-28 |
| Primary Completion | 2027-04-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 33 participants in total. It began in 2024-05-28 with a primary completion date of 2027-04-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine the efficacy and safety of atezolizumab-bevacizumab combination therapy plus stereotactic body radiotherapy(SBRT) in patients with advanced hepatocellular carcinoma, Subjects will start SBRT for one or more primary cancers and/or metastatic lesions and no more than 5 sites within two month before and after the start date of atezolizumab-bevacizumab combination therapy. In this study, it is expected to improve the treatment response rate of atezolizumab-bevacizumab therapy, which is currently first-line chemotherapy but has a low treatment response rate.
Eligibility Criteria
Inclusion Criteria: 1. Age 19 to 80 years old 2. Liver function Child-Pugh class A 3. ECOG 0-1 4. Patient clinically or pathologically diagnosed with hepatocellular carcinoma 5. Advanced hepatocellular carcinoma that is inoperable 6. Satisfies the dose limits for normal organs and lesions of an appropriate size to be included in the scope of radiotherapy. Exclusion Criteria: 1. Brain metastases 2. Have a history of malignancy other than hepatocellular carcinoma within the last 5 years (except for malignancies with little risk of metastasis or death, e.g., adequately treated cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, tubular carcinoma in situ, or stage 1 uterine cancer.) 3. Subjects with a high probability of untreated gastric or esophageal varices or bleeding 4. Serious uncontrolled medical comorbidities 5. History of liver transplant surgery 6. Autoimmune liver disease
Contact & Investigator
Hwakyung BYUN, Phd
PRINCIPAL INVESTIGATOR
Severance Hospital
Frequently Asked Questions
Who can join the NCT06595108 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 80 Years, studying Advanced Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06595108 currently recruiting?
Yes, NCT06595108 is actively recruiting participants. Contact the research team at hkbyun05@yuhs.ac for enrollment information.
Where is the NCT06595108 trial being conducted?
This trial is being conducted at Yongin-si, South Korea.
Who is sponsoring the NCT06595108 clinical trial?
NCT06595108 is sponsored by Yonsei University. The principal investigator is Hwakyung BYUN, Phd at Severance Hospital. The trial plans to enroll 33 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.